Role of complement in myasthenia gravis

Area of Science:

• Neuroimmunology
• Complement system biology
• Neuromuscular disorders

Background:

• Myasthenia gravis (MG) is a neuroimmune disorder characterized by autoantibodies targeting the acetylcholine receptor complex.
• Patients experience ocular and generalized muscle weakness, potentially leading to fatal bulbar muscle involvement.
• IgG1 and IgG3 subtypes of acetylcholine receptor antibodies activate the complement system, contributing to neuromuscular junction damage.

Purpose of the Study:

• To review the role of the complement system in myasthenia gravis pathogenesis.
• To summarize current evidence on the efficacy and safety of complement therapies in MG.
• To discuss approved and investigational complement therapies for myasthenia gravis.

Main Methods:

• Literature review of studies on complement involvement in MG.
• Analysis of randomized controlled trials (RCTs) and real-world data for complement therapies.
• Summary of safety and efficacy data for approved and investigational treatments.

Main Results:

• Complement system activation is a key mechanism in neuromuscular junction damage in MG.
• Complement therapies, initially developed for paroxysmal nocturnal hemoglobinuria, show promise in MG.
• Available data suggest efficacy and a manageable safety profile for complement inhibitors in MG.

Conclusions:

• The complement system is a critical factor in myasthenia gravis pathophysiology.
• Complement-targeted therapies represent a significant advancement in managing myasthenia gravis.
• Further research and clinical data are essential for optimizing complement-based treatment strategies.